CARDIOVASCULAR AUTOIMMUNE DISEASE PANEL AND METHODS OF USING SAME

    公开(公告)号:WO2008080030A3

    公开(公告)日:2008-07-03

    申请号:PCT/US2007/088477

    申请日:2007-12-21

    Abstract: Provided herein among other things are diagnostic tests, methods of use, and kits for the assessment and management of cardiovascular autoimmune disease and risk of cardiovascular autoimmune disease. Assay methods of the invention can be employed among other things to identify cardiovascular autoimmune disease, or risk thereof, in subjects who have cardiovascular disease, an autoimmune disease, or who are related to an individual with an autoimmune disease. The method can be employed for testing of a subject that exhibits symptoms of cardiovascular disease, as well as of a subject that is apparently healthy and does not yet exhibit symptoms of cardiovascular disease, but may with time. In one embodiment, the invention also provides a method of determining whether a subject having, or at risk for, a cardiovascular disease is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.

    ASSAY FOR CARDIAC TROPONIN AUTOANTIBODIES
    3.
    发明申请
    ASSAY FOR CARDIAC TROPONIN AUTOANTIBODIES 审中-公开
    CARDIAC TROPONIN AUTOANTIBODIES的测定

    公开(公告)号:WO2008051761A2

    公开(公告)日:2008-05-02

    申请号:PCT/US2007/081606

    申请日:2007-10-17

    Abstract: The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.

    Abstract translation: 本发明尤其提供基于测定心肌肌钙蛋白自身抗体的方法和试剂盒,或者结合心肌肌钙蛋白的测定和/或作为心脏病理学的独立指示物,例如心肌炎,心肌病 和/或缺血性心脏病。 本发明的测定方法尤其可用于鉴定患有自身免疫性疾病或与患有自身免疫性疾病的个体相关的个体的心脏病理学或其风险。 在具体的实施方案中,本发明还提供了确定患有心脏病理学或处于心脏病理学危险中的受试者是否是免疫抑制疗法或免疫吸收疗法的候选者的方法。 本发明还提供对于实施本发明的方法有用的试剂盒和试剂盒组分。

    CARDIOVASCULAR AUTOIMMUNE DISEASE PANEL AND METHODS OF USING SAME
    5.
    发明申请
    CARDIOVASCULAR AUTOIMMUNE DISEASE PANEL AND METHODS OF USING SAME 审中-公开
    心血管自动免疫疾病小组及其使用方法

    公开(公告)号:WO2008080030A2

    公开(公告)日:2008-07-03

    申请号:PCT/US2007088477

    申请日:2007-12-21

    CPC classification number: G01N33/564 G01N2800/32

    Abstract: Provided herein among other things are diagnostic tests, methods of use, and kits for the assessment and management of cardiovascular autoimmune disease and risk of cardiovascular autoimmune disease. Assay methods of the invention can be employed among other things to identify cardiovascular autoimmune disease, or risk thereof, in subjects who have cardiovascular disease, an autoimmune disease, or who are related to an individual with an autoimmune disease. The method can be employed for testing of a subject that exhibits symptoms of cardiovascular disease, as well as of a subject that is apparently healthy and does not yet exhibit symptoms of cardiovascular disease, but may with time. In one embodiment, the invention also provides a method of determining whether a subject having, or at risk for, a cardiovascular disease is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.

    Abstract translation: 除此之外,本文提供了诊断测试,使用方法以及用于评估和管理心血管自身免疫疾病和心血管自身免疫疾病风险的试剂盒。 本发明的测定方法尤其可用于鉴定患有心血管疾病,自身免疫性疾病或与患有自身免疫性疾病的个体有关的个体的心血管自身免疫疾病或其风险。 该方法可用于测试表现出心血管疾病症状的受试者以及明显健康并且尚未表现出心血管疾病症状但可能随时间变化的受试者。 在一个实施方案中,本发明还提供了确定患有心血管疾病或处于心血管疾病风险中的受试者是否是用于免疫抑制疗法或免疫吸收疗法的候选者的方法。 本发明还提供对于实施本发明的方法有用的试剂盒和试剂盒组分。

    DIAGNOSTIC METHOD FOR PROTEINACEOUS BINDING PAIRS, CARDIOVASCULAR CONDITIONS AND PREECLAMPSIA
    6.
    发明申请
    DIAGNOSTIC METHOD FOR PROTEINACEOUS BINDING PAIRS, CARDIOVASCULAR CONDITIONS AND PREECLAMPSIA 审中-公开
    蛋白质结合对照,心血管病和前列腺炎的诊断方法

    公开(公告)号:WO2007059065B1

    公开(公告)日:2007-09-13

    申请号:PCT/US2006044059

    申请日:2006-11-14

    CPC classification number: G01N33/566 G01N33/689 G01N33/74 G01N2800/368

    Abstract: Method of measuring the quantity of a first proteinaceous specific binding partner (sbp) in a biological sample comprising detecting the binding of the first proteinaceous sbp with a labeled second proteinaceous sbp, wherein neither the first or second sbp is an antibody or fragment thereof, which is preferably a method of determining the amount of sFlt-1, particularly free sFlt-1, and the amount of PlGF, particularly free PlGF, in a sample, which is preferably used in a method of predicting risk of preeclampsia comprising comparing free PlGF to free sFlt-1.

    Abstract translation: 测量生物样品中第一蛋白质特异性结合配偶体(sbp)的量的方法,包括检测第一蛋白质sbp与标记的第二蛋白质sbp的结合,其中第一或第二sbp都不是抗体或其片段,其中 优选地是测定样品中sFlt-1的量,特别是游离的sFlt-1以及PlGF的量,特别是游离PlGF的量,其优选用于预测先兆子痫风险的方法中,其包括将游离PlGF与 免费sFlt-1。

    ASSAY FOR CARDIAC TROPONIN AUTOANTIBODIES
    8.
    发明申请
    ASSAY FOR CARDIAC TROPONIN AUTOANTIBODIES 审中-公开
    CARDIAC TROPONIN AUTOANTIBODIES的测定

    公开(公告)号:WO2008051761A3

    公开(公告)日:2008-11-13

    申请号:PCT/US2007081606

    申请日:2007-10-17

    Abstract: The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.

    Abstract translation: 本发明还提供了基于心肌肌钙蛋白自身抗体测定的方法和试剂盒,其与心肌肌钙蛋白的测定和/或作为心脏病理学的独立指标,例如心肌炎,心肌病和/或缺血性心脏病。 本发明的测定方法可以用于鉴别患有自身免疫疾病或与具有自身免疫疾病的个体相关的受试者的心脏病理学或其风险。 在具体实施方案中,本发明还提供了确定具有或具有心脏病理危险的受试者是免疫抑制治疗或免疫吸收治疗的候选者的方法。 本发明还提供了可用于实施本发明方法的试剂盒和试剂盒组分。

    DIAGNOSTIC METHOD FOR PROTEINACEOUS BINDING PAIRS, CARDIOVASCULAR CONDITIONS AND PREECLAMPSIA
    9.
    发明申请
    DIAGNOSTIC METHOD FOR PROTEINACEOUS BINDING PAIRS, CARDIOVASCULAR CONDITIONS AND PREECLAMPSIA 审中-公开
    蛋白质结合对,心血管病和前列腺疾病的诊断方法

    公开(公告)号:WO2007059065A3

    公开(公告)日:2007-07-26

    申请号:PCT/US2006044059

    申请日:2006-11-14

    CPC classification number: G01N33/566 G01N33/689 G01N33/74 G01N2800/368

    Abstract: Method of measuring the quantity of a first proteinaceous specific binding partner (sbp) in a biological sample comprising detecting the binding of the first proteinaceous sbp with a labeled second proteinaceous sbp, wherein neither the first or second sbp is an antibody or fragment thereof, which is preferably a method of determining the amount of sFlt-1, particularly free sFlt-1, and the amount of PlGF, particularly free PlGF, in a sample, which is preferably used in a method of predicting risk of preeclampsia comprising comparing free PlGF to free sFlt-1.

    Abstract translation: 测量生物样品中第一蛋白质特异性结合配偶体(sbp)的量的方法,包括检测第一蛋白质sbp与标记的第二蛋白质sbp的结合,其中第一或第二sbp都不是抗体或其片段,其 优选是确定优选用于预测先兆子痫风险的方法中的样品中sFlt-1,特别是游离sFlt-1的量和PlGF,尤其是游离PlGF的量的方法,其包括将游离PlGF与 免费sFlt-1。

Patent Agency Ranking